SPY390.38+10.02 2.63%
DIA316.65+7.20 2.33%
IXIC13,565.30+372.95 2.83%

BRIEF-Pfizer Confirms U.S. Patent Term Extension For Ibrance® (Palbociclib) Until March 2027

· 02/05/2021 06:48
BRIEF-Pfizer Confirms U.S. Patent Term Extension For Ibrance® (Palbociclib) Until March 2027

- Pfizer Inc PFE.N:

  • PFIZER CONFIRMS U.S. PATENT TERM EXTENSION FOR IBRANCE® (PALBOCICLIB) UNTIL MARCH 2027

  • PFIZER INC - CERTIFICATE EXTENDS TERM OF U.S. PATENT NO. RE47,739 ('739) BY MORE THAN FOUR YEARS UNTIL MARCH 5, 2027

  • PFIZER INC - PTE WILL BE LISTED IN APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS (COMMONLY KNOWN AS ORANGE BOOK), PUBLISHED BY FDA

  • PFIZER INC -PATENT TERM EXTENSION FOR IBRANCE DOES NOT INCLUDE POTENTIAL PEDIATRIC EXCLUSIVITY

Source text for Eikon: ID:nBw5PMG7Na

Further company coverage: PFE.N


((Reuters.Briefs@thomsonreuters.com;))